A Limited Food Effect Study of Gabapentin 800 mg Tablets

NCT ID: NCT00865631

Last Updated: 2010-08-17

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 18 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 1999-06-30
• Study Completion Date: 1999-06-30

Brief Summary

The purpose of this study is to compare the relative bioavailability of 800 mg Gabapentin Tablets by Purepac Pharmaceutical Co. with that of 400 mg (2 x 400 mg) NEURONTIN® by Parke-Davis following a single oral dose (1 x 800 mg tablet) or (2 x 400 mg capsules) in healthy adult male volunteers under non-fasting conditions, and will compare the differences in plasma levels after dosing the test formulation with and without food.

Detailed Description

Study Type: Interventional Study Design: Randomized, single-dose, three-way crossover under fed and fasting conditions

Official Title: A Limited Food Effect Study of 800 mg Gabapentin Tablets versus 400 mg Gabapentin Capsules

Further study details as provided by Actavis Elizabeth LLC:

Primary Outcome Measures:

Rate and Extend of Absorption

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Blinding Strategy: NONE

Study Groups

A

Gabapentin 800 mg tablets, single dose (1 tablet)

Group Type: EXPERIMENTAL

Gabapentin 800 mg tablets, single dose (1 tablet)

Intervention Type: DRUG

A: Experimental Subjects received Purepac formulated products under fasting conditions

Gabapentin 800 mg tablets, single dose (1 tablet)

Intervention Type: DRUG

A: Experimental Subjects received Purepac formulated products under non-fasting conditions

B

NEURONTIN® 400 mg capsules, single dose (2 capsules)

Group Type: ACTIVE_COMPARATOR

NEURONTIN® 400 mg capsules, single dose (2 capsules)

Intervention Type: DRUG

B: Active comparator Subjects received Parke-Davis formulated products under non-fasting conditions

Interventions

Gabapentin 800 mg tablets, single dose (1 tablet)

A: Experimental Subjects received Purepac formulated products under fasting conditions

Intervention Type: DRUG

NEURONTIN® 400 mg capsules, single dose (2 capsules)

B: Active comparator Subjects received Parke-Davis formulated products under non-fasting conditions

Intervention Type: DRUG

Gabapentin 800 mg tablets, single dose (1 tablet)

A: Experimental Subjects received Purepac formulated products under non-fasting conditions

Intervention Type: DRUG

Other Intervention Names

Gabapentin; Gabapentin; Gabapentin

Eligibility Criteria

Inclusion Criteria

• Screening Demographics: All volunteers selected for this study will be healthy men 18 to 45 years of age, inclusive, at the time of dosing. The weight range will not exceed ± 15% for height and body frame as per Desirable Weights for Men• 1983 Metropolitan Height and Weight Table.
• Screening Procedures: Each volunteer will complete the screening process within 28 days prior to Period I dosing. Consent documents for both the screening evaluation and HIV antibody determination will be reviewed, discussed, and signed by each potential participant before full implementation of screening procedures.
• Screening will include general observations, physical examination, demographics, medical and medication history, an electrocardiogram, sitting blood pressure and heart rate, respiratory rate and temperature. The physical examination will include, but may not be limited to, an evaluation of the cardiovascular, gastrointestinal, respiratory and central nervous systems.
• The screening clinical laboratory procedures will include:

• HEMATOLOGY: hematocrit, hemoglobin, WBC count with differential, RBC count, platelet count;
• CLINICAL CHEMISTRY: serum creatinine, BUN, glucose, AST(GOT), ALT(GPT), albumin, total bilirubin, total protein, and alkaline phosphatase;
• HIV antibody and hepatitis B surface antigen screens;
• URINALYSIS: pH, albumin, sugar, acetone, bilirubin, occult blood and microscopic analysis; and
• URINE DRUG SCREEN: ethyl alcohol. amphetamines. barbiturates, benzodiazepines, cannabinoids. cocaine metabolites, opiates and phencyclidine.

Exclusion Criteria

• Volunteers with a recent history of drug or alcohol addiction or abuse.
• Volunteers with the presence ofa clinically significant disorder involving the cardiovascular, respiratory, renal, gastrointestinal, immunologic, hematologic, endocrine, or neurologic system(s) or psychiatric disease (as determined by the medical investigator).
• Volunteers whose clinical laboratory test values are outside the accepted reference range and when confirmed on re-examination are deemed to be clinically significant.
• Volunteers demonstrating a positive hepatitis B surface antigen screen or a reactive HIV antibody screen.
• Volunteers demonstrating a positive drug abuse screen when screened for this study.
• Volunteers with a history of allergic response(s) to gabapentin or related drugs.
• Volunteers with a history of clinically significant allergies including drug allergies.
• Volunteers with a clinically significant illness during the 4 weeks prior to Period I dosing (as determined by the medical investigator.
• Volunteers who currently use tobacco products.
• Volunteers who have taken any drug known to induce or inhibit hepatic drug - Volunteers who report donating greater than 150 mL of blood within 30 days prior to Period I dosing. All subjects will be advised not to donate blood for four weeks after completing the study.
• Volunteers who have donated plasma (e.g. plasmaphoresis) within 14 days prior to Period I dosing. All subjects will be advised not to donate plasma for four weeks after completing the study.
• Volunteers who report receiving any investigational drug within 30 days prior to Period I dosing.
• Volunteers who report taking any systemic prescription medication in the 14 days prior to Period I dosing.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

Actavis Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Actavis Inc

Principal Investigators

James D. Carlson,, Pharm. D.

Role: PRINCIPAL_INVESTIGATOR

PRACS Institute, Ltd.

Locations

PRACS Institute, Ltd.

Fargo, North Dakota, United States

Countries

United States

Other Identifiers

P99-229

Identifier Type: -

Identifier Source: org_study_id